Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 283-288 , October 2001

Chemotherapy in patients with metastatic or relapsed germ-cell tumours

  • O. Rick

      Affiliations

    • Klinik für Innere Medizin m.S. Hämatologie/Onkologie, Universitätsklinikum Charité, Campus Mitte, Humboldt Universität, Berlin
    • ,
  • W. Siegert

      Affiliations

    • Klinik für Innere Medizin m.S. Hämatologie/Onkologie, Universitätsklinikum Charité, Campus Mitte, Humboldt Universität, Berlin
    • ,
  • J. Beyer

      Affiliations

    • Klinik für Innere Medizin m.S. Hämatologie/Onkologie, Klinikum der Philipps Universität, Marburg

References 

  1. Bosl G, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242–253
  2. J Clin Oncol. 1997;15:594–603
  3. Loehrer PJ, Lauer R, Roth BJ. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988;109:540–546
  4. Bokemeyer C, Kollmannsberger C, Meisner C. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol. 1999;17:3450–3456
  5. Rick O, Bokemeyer C, Beyer J. Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001;19:81–88
  6. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1777–1781
  7. Birch R, Williams S, Cone A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986;4:400–407
  8. Bower M, Newlands ES, Holden L. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997;8:477–483
  9. Kaye SB, Mead GM, Fossa SD. Intensive induction sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organisation for Research and Treatment of Cancer study. J Clin Oncol. 1998;16:692–701
  10. Culine S, Theodore C, Bekradda M. Experience with bleomycin, etoposide, cisplatin (BEP) an alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II)/vinblastine, bleomycine (VB (IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol. 1997;20:184–188
  11. de Wit R, Stoter G, Sleijfer DT. Four cycles of BEP versus an alternating regimen and PVB and PEB in patients with poor prognosis metastatic testicular non-seminoma: A randomized study of the EORTC-Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995;71:1311–1314
  12. Williams S, Birch R, Einhorn LH. Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastin or etoposid. New Engl J Med. 1987;316:1435–1440
  13. Chevreau C, Droz JP, Pico JL. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminmatous germ cell tumours: Preliminary results of a French randomized trial. Eur Urol. 1993;23:213–217
  14. Motzer RJ, Mazumdar M, Bajorin DF. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546–2552
  15. Bokemeyer C, Harstrick A, Beyer J. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors: German Testicular Cancer Study Group. Semin Oncol. 1998;25:24–32
  16. Bosl GJ, Geller NL, Cirrincione C. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983;43:3403–3407
  17. Lancet. 1985;1:8–12
  18. Stoter G, Sylvester R, Sleijfer DT. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from an EORTC multiinstitutional phase III study. Cancer Res. 1987;47:2414–2418
  19. Droz JP, Kramer A, Ghosn M. Prognostic factors in advanced nonseminomatous testicular cancer. Cancer. 1988;62:564–568
  20. Aass N, Klepp O, Stahl-Cavallin E. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicentre experience. J Clin Oncol. 1991;9:818–826
  21. Bokemeyer C, Beyer J, Metzner B, Rüther U, Harstrick A, Weissbach L, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol. 1996;7:31–34
  22. Motzer RB, Sheinfeld J, Mazumdar M. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413–2418
  23. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173–1180
  24. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W. Treatment intensification in disseminated germ-cell tumors. World J Urol. 1994;12:207–213
  25. Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol. 1997;15:1427–1431
  26. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–2504
  27. Rick O, Siegert W, Beyer J. High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany. Int J Cancer. 1999;83:839–840
  28. Rodenhuis S, de Wit R, de Mulder P HM, Keizer HJ, Sleijfer DT, Lalisng RI, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol. 1999;10:1467–1473
  29. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol. 1996;14:2638–2645
  30. Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol. 1994;12:1390–1393
  31. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, et al. Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non- seminomatous germ cell tumours. Br J Cancer. 1999;80:1392–1399
  32. Rick O, Beyer J, Schwella N. Amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol. 2001;12:1151–1155

PII: S0305-7372(01)90230-0

doi: 10.1053/ctrv.2001.0230

Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 283-288 , October 2001

Article Tools